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Summary
Anaphylaxis in pregnancy is a rare but severe complication for bothmother and infant. Population-based data on
anaphylaxis in pregnancy are lacking from mainland European countries. This multinational study presents the
incidence, causative agents, management and maternal and infant outcomes of anaphylaxis in pregnancy. This
descriptive multinational study used a combination of retrospective (Finnish medical registries) and prospective
population-based studies (UK, France, Belgium and the Netherlands) to identify cases of anaphylaxis. Sixty-five
cases were identified among 4,446,120 maternities (1.5 per 100,000 maternities; 95%CI 1.1–1.9). The incidence
did not vary between countries. Approximately three-quarters of reactions occurred at the time of delivery. The
most common causes were antibiotics in 27 women (43%), and anaesthetic agents in 11 women (17%; including
neuromuscular blocking drugs, 7), which varied between countries. Anaphylaxis had very poor outcomes for one
in seven mothers and one in seven babies; the maternal case fatality rate was 3.2% (95%CI 0.4–11.0) and the
neonatal encephalopathy rate was 14.3% (95%CI 4.8–30.3). Across Europe, anaphylaxis related to pregnancy is
rare despite having amultitudeof causative agents anddifferent antibiotic prophylaxis protocols.
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Introduction
Anaphylaxis is a severe immune hypersensitivity disorder
that is rapid in onset and occurs without premonitory signs.
It often involves compromise to the cardiovascular,
respiratory, cutaneous and gastro-intestinal systems, and in
pregnancy can result in severe morbidity and mortality for
bothmother and infant [1].
The majority of the literature on anaphylaxis in
pregnancy consists of case series and case reports, with
limited high quality studies [1, 2]. To date, only two
population-based studies have described anaphylaxis in
pregnancy; a UK study showed an incidence of 1.6 per
100,000 maternities [3], while a national hospital database
study in the USA identified an incidence of 3.8 per 100,000
pregnancy-related hospitalisations [4]. There are no
population-based studies examining anaphylaxis in
pregnancy in continental European countries.
As anaphylaxis in pregnancy is very rare, national
studies from small populations may not accrue sufficient
cases unless they are conducted for long periods; on the
other hand, multinational studies are able to provide larger
numbers that enable more precise estimates of incidence
[5]. This study aimed to estimate the incidence, causative
agents, management and outcomes of anaphylaxis in
pregnancy across Europe using both prospective and
retrospective data collectionmethods.
Methods
Anaphylaxis is defined as a severe, life-threatening
generalised or systemic hypersensitivity reaction [6]. It is
diagnosed by the presence of at least one of the following
criteria: a life-threatening airway problem; life-threatening
breathing problem; life-threatening circulatory problem
(Fig. 1); in addition, there is sudden onset and rapid
progression of symptoms. For inclusion in this study, such a
reaction must have occurred at any point during pregnancy
or up to 48 h after delivery. In addition, women were not
included if the senior attending obstetrician or anaesthetist
did not consider the case to be anaphylaxis on clinical
grounds.
Women that had anaphylaxis during pregnancy were
prospectively identified at a national level in the UK,
Netherlands, France and Belgium. The UK data were
collected using the UK Obstetric Surveillance System [7];
this study has been published previously [3]. In Belgium and
the Netherlands, cases were notified through the respective
Belgian Obstetric Surveillance System (B.OSS) and
Netherlands Obstetric Surveillance System (NethOSS) [8, 9].
Women in Finland were retrospectively identified in the
Finnish Medical Birth Registry linked to the Hospital
Discharge Register [10]. A detailed description of data
collection is presented in Table S1, and the methodology in
each country is presented in Table S2.
The online data collection form used in France, Belgium,
Finland and the Netherlands was a modified version of the
UKOSS data collection form, with the majority of variables
being the same. Identification of the study population is
shown in Figure S1. Anonymised information on maternal
characteristics, previous medical history, suspected causes
andmanagement of anaphylaxis, and maternal and perinatal
outcomes of notified cases were entered. The online data
collection used theOpenClinica system [11].
The incidence is presented as rate per 100,000
maternities, with the 95%CI estimated using the binomial
distribution. Initially, the characteristics of women,
management, causative agents and outcomes between the
countries were checked to assess comparability. The Chi-
squared test was used to assess statistical difference
between categorical variables and countries; if there were
no statistically significant differences between the countries,
they are presented as a combined cohort. Management was
different between the UK and mainland Europe, and as a
consequence the results are presented separately. Women
were categorised according to when the anaphylactic
reaction occurred in relation to delivery. These groups
included: antenatal (not in delivery suite or theatre);
intrapartum (immediately before delivery); and post-
delivery (up to 48 h after delivery). Women were
categorised using the time of anaphylaxis and time of
delivery, suspected causative agent and additional
information included in the case notes. It is possible that
management and causative agents may have changed over
a 10-year period, so a sensitivity analysis was carried out in
Finnish women who had anaphylaxis before 2012 to assess
any difference in the management and causative agents.
Analyses were completed using Stata version 13 (StataCorp
LLC, College Station, TX, USA).
Results
There were 65 confirmed cases of anaphylaxis in 4,446,120
maternities, giving an estimated incidence of 1.5 per
100,000 maternities (95%CI 1.1–1.9; Table 1). The
Netherlands was unable to collect data for its two reported
cases due to changes in the General Data Protection
Regulation guidance given to obstetricians in the
Netherlands. Results are presented for the remaining 63
cases.
The characteristics of the women are given in Table 2.
The majority of reactions, 35 (56%), occurred before
delivery, with 16 (25%) reactions occurring in the antenatal
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period (not related to delivery), and 19 (30%) occurring
immediately before delivery. Reactions immediately after
delivery made up over a third of all reactions (Fig. 2). The
timing of reactions according to country and mode of
delivery is presented in Table S3. Three out of fourteen
women who had a known penicillin allergy were given a
penicillin-based antibiotic resulting in an anaphylactic
reaction; two women with a known penicillin allergy had a
reaction to a cephalosporin.
Themajority of the reactions that occurred immediately
before delivery, 18 (95%) occurred in women having a
caesarean section. Four reactions occurred after
administration of anaesthetic agents, three followed
suxamethonium and one followed administration of spinal
anaesthesia. Figure S2 and Table S4 show that there was
only one reaction caused by prophylactic antibiotics before
a caesarean section in France and Belgium, and there were
no cases in Finland. Two of the three reactions that were the
result of antibiotics given for the prophylaxis of Group B
streptococcus occurred in France. In those who had
reactions after delivery, 12 (43%) women had a reaction to
an agent given for the management of a postpartum
haemorrhage.
Reactions related to anaesthesia occurred in 11 (17%)
women (Fig. 2). The suspected agents were:
suxamethonium 6; suxamethonium or thiopental 1; lidocaine
1; sugammadex 1; unspecified agent but temporally related
to anaesthesia 2.
IgE testing was completed in 9 (32%) women in
mainland Europe (this question was not asked in the UK).
Seven of nine women had a specified antigen identified;
four had an anaesthetic agent confirmed (suxamethonium
3; sugammadex 1) and three had a penicillin-based agent
The presence of at least one of the following:
1. A life-threatening airway problem is taken to include:
- Laryngeal or pharyngeal oedema
- Hoarse voice
- Stridor
2.  A life-threatening breathing problem is taken to include:
- Shortness of breath and raised respiratory rate
- Wheeze (laryngospasm or bronchospasm)
- Decreased oxygen saturaons
- Confusion secondary to hypoxia
- Cyanosis
- Respiratory exhauson or respiratory arrest
3. A life-threatening circulatory problem is taken to include:
- Signs of shock such as faintness, pallor or clammy skin
- Tachycardia > 100 beats min-1
- Systolic pressure < 90 mmHg or diastolic pressure < 60 mmHg or 
measured hypotension
- Decreasing level of consciousness
- Signs of ischaemia on ECG
- Cardiac arrest
Figure 1 Clinical criteria for a diagnosis of anaphylaxis
Table 1 Incidence of anaphylaxis in pregnancy across
countries.
Country
Anaphylaxis
in pregnancy Maternities
Rate
per 100,000
(95%CI)
UK 35 2,324,522 1.5 (1.1–2.1)
France 17 1,125,495 1.5 (0.9–2.4)
Finland 9 642,430 1.4 (0.6–2.7)
Netherlandsa 2 173,013 1.2 (0.1–4.2)
Belgium 2 180,660 1.1 (0.1–4.0)
Combined 65 4,446,120 1.5 (1.1–1.9)
aExcluded from further analysis – see text.
Table 2 Characteristics of 63 women with anaphylaxis in
pregnancy in the INOSS study. Values are mean (SD),
number (proportion) ormedian (IQR [range]).
Physical characteristics
Agea 31.7 (6.7)
Smoking statusb
Never/ex-smoker 45 (77.6%)
Smokedduringpregnancy 13 (22.4%)
Gestational age at deliveryc 39 (37–40 [27–41])
BMId 26 (23–29 [18.5–44.6])
Obstetric characteristics
Parity
0 20 (31.7%)
≥ 1 43 (68.3%)
Previous pregnancy problem 20 (31.7%)
Multiple pregnancy 4 (6.3%)
Previousmedical history
Previous anaphylactic reaction 7 (11.1%)
Knowndrug allergya 19 (30.6%)
Penicillin-based 14 (22.6%)
Other 5 (8.1%)
History of atopye 20 (32.8%)
History of any allergic reaction 34 (54.0%)
History of any allergic
reaction or atopy
38 (60.3%)
an = 62.
bn = 58.
cn = 56.
dn = 59.
en = 61.
© 2020 TheAuthors.Anaesthesiapublished by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists 1471
McCall et al. | Anaphylaxis in pregnancy in Europe Anaesthesia 2020, 75, 1469–1475
confirmed. Peri-operative anaphylaxis occurred in 36 (57%)
women. The suspected causative agents for these women
were as follows: 20 (56%) women had a reaction to an
antibiotic; anaesthetic agents caused 11 (31%) reactions;
and five (14%) reactions were the result of other agents. No
anaesthetic-related reaction was associated with epidural
analgesia during labour.
The UK and mainland European countries had similar
proportions of women receiving oxygen and intravenous
fluid to manage the reaction (Table 3). There was a
difference in the proportion of women receiving adrenaline,
19 (68%) in Finland, Belgium and France combined vs. 27
(93%; p = 0.016) in the UK. A sensitivity analysis was
performed without including the women from Finland who
had a reaction before 2012. In this restricted cohort, 44
(85%) women received adrenaline, while 45 (88%) received
corticosteroid and 29 (67%) received antihistamine.
Twowomen died giving a case fatality rate of 3.2% (95%
CI 0.4–11.0), one from suxamethonium and one from
amoxicillin combined with clavulanic acid (Co-amoxyclav;
Table 4). There were no perinatal deaths or stillbirths to
mothers who had anaphylaxis before delivery. The
proportion affected by neonatal encephalopathy was 14.3%
(95%CI: 4.8–30.3; Table 5).
Figure 2 Timing of anaphylaxis in the INOSS study and suspected causative agents. *multiple agents including latex, penicillin,
prostaglandin and temazepam. CS, caesarean section; GBS, GroupB streptococcus; NSAID, non steroidal anti-inflammatory
drug.
Table 3 Management of anaphylaxis in pregnancy in UK
compared with European nations. Values are number
(proportion of thosewith information).
France,
Belgiumand
Finland (n = 28)
UK
(n = 35)
Combined
(n = 63)
High flowoxygen
Yes 22 (88.0%) 27 (79.4%) 49 (83.1%)
No 3 (12.0%) 7 (20.6%) 10 (16.9%)
Intravenous fluid
Yes 25 (92.6%) 30 (85.7%) 55 (88.7%)
No 2 (7.4%) 5 (14.3%) 7 (11.3%)
Epinephrine
Yes 19 (67.9%) 27 (93.1%) 46 (80.7%)
No 9 (32.1%) 2 (6.9%) 11 (19.3%)
Antihistamine
Yes 3 (20.0%) 26 (86.7%) 29 (64.4%)
No 12 (80.0%) 4 (13.3%) 16 (35.6%)
Corticosteroid
Yes 17 (77.3%) 32 (97.0%) 49 (89.1%)
No 5 (22.7%) 1 (3.0%) 6 (10.9%)
Tryptase tested 14 (53.8%) 30 (85.7%) 44 (72.1%)
Tryptase raised 11 (84.6%) 8 (32.0%) 19 (50.0%)
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Discussion
There appears to be a similar incidence of anaphylaxis in
pregnancy across five European countries, affecting 1.5 per
100,000 women among almost 4.5 million births. Most
reactions occurred at or around the time women gave birth.
There was variation in the diagnosis and management of
anaphylaxis between the UK andmainland Europe.
The main causative agents for anaphylaxis were
antibiotics and anaesthetic agents, in particular
neuromuscular blocking drugs [1, 2]. Similar to previous
studies, the most commonly suspected causative agent
was an antibiotic [2, 12], given either prophylactically for
Group B streptococcus [12–14] or for surgical
prophylaxis [2]. Three women had anaphylaxis following
antibiotic administered for Group B streptococcus,
including two in France and one in the UK. Over a fifth
of reactions were found to be the direct result of
prophylactic use of antibiotics at the time of caesarean
section [15, 16]. Half of these reactions occurred once
the caesarean section had been carried out. Importantly,
had the antibiotics been administered before surgery,
the burden of infant morbidity may have been higher. In
Finland and France, prophylactic antibiotics were given
at induction (before skin incision). The majority of
women who had a peri-operative reaction did not
receive an IgE specific test to confirm the causative
agent involved, which would have important implications
for future surgical procedures.
The findings from this study are similar to that of the 6th
National Audit Project (NAP6); in particular, antibiotics and
neuromuscular blocking drugs were the primary suspected
causative agents [17]. It is interesting to note that
suxamethonium was the only neuromuscular blocking
agent used in this study, whereas rocuronium was the most
common agent in NAP6 [17]. This may be explained by
preferential use of suxamethonium during induction of
general anaesthesia at caesarean section [18]. Furthermore,
a previous study in France reported that neuromuscular
blocking drugs were the main causes of maternal death
from anaphylaxis [19]. It is important that allergy to
neuromuscular blocking drugs is identified to guide
management of future general anaesthesia.
Three women who had known penicillin allergies were
administered the drug resulting in an anaphylactic reaction.
This highlights that these cases were preventable, and
indicates that a detailed drug allergy history must be taken at
booking and immediately before administration of any
antibiotics. Human factors have been demonstrated to play a
role inmedication errors [20]. TheWorld HealthOrganization
surgical checklist should be undertaken before caesarean
section to reduce the risk of medical error [21], and we
suggest that this concept might be extended to women
having vaginal delivery.
The study findings show that an even lower proportion
of women received adrenaline in mainland Europe
compared with the UK. The NAP6 project stated that there
was a lowmortality rate from anaphylaxis, which was likely to
be a consequence of the early detection and management
of reactions [17]. Current guidelines recommend
adrenaline as first line management of anaphylaxis, and
timely use will prevent hypoxia and mortality [22–24]. In
order to improve management, the anaphylaxis algorithm
should be immediately available in operating theatres and
delivery suites [6, 25].
This study has shown poor outcomes for women
who have anaphylaxis, with a 3.5% case fatality rate and
11% of women suffering additional severe morbidity.
The Confidential Enquiries into Maternal Deaths in the
UK and France report a similar case fatality for
anaphylaxis related to pregnancy [19, 26]. Furthermore,
there were severe outcomes for infants, with a third of
Table 4 Severe maternal outcomes in 63 women with
anaphylaxis. Values are number (proportion).
Death 2 (3.2%)
Severemorbidity includingdeath 9 (14.3%)
Cardiac arrest 3 (4.8%)
Thrombotic event 2 (3.2%)
Othera 4 (6.3%)
ICU admissionb 28 (45.2%)
Intubation requiredc 13 (48.1%)
aOne each of: acute renal injury, acute cardiac failure and
thrombocytopenia; respiratory distress or failure; stress
cardiomyopathy; hypoxic brain injury.
bn = 62.
cOnly collected in France, Belgiumand Finland (n = 27).
Table 5 Perinatal outcome information available from 35
infants of women who had an anaphylactic reaction before
delivery. Values are number (proportion).
Perinatal deatha 0
Neonatal ICU admissionb 12 (35.3%)
Neonatal encephalopathy 5 (14.3%)
Baby cooled 4 (11.4%)
Unknown 1 (2.9%)
Apgar ≤ 6@ 5 minc 5 (16.1%)
N.B. four infantswere included from twomultiple pregnancies.
an = 33.
bn = 34.
cn = 31.
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infants admitted to neonatal ICU, one in six infants with
abnormal Apgar scores, and one in seven with neonatal
encephalopathy that required therapeutic cooling. This
is consistent with previous case series and literature
reviews [1, 2].
This multinational study, which included three countries
with obstetric surveillance systems and two other countries
using similar methodologies, has provided a large-scale
study of a very rare complication of pregnancy. The
prospective study design has the added advantage of being
able to use a uniform case definition across nations. For the
Finnish registry data, the method of case ascertainment
allowed routinely identified cases of anaphylaxis to be
validated against hospital records. This prevented false
positives frombeing included in the studydataset.
Prospective studies have the same limitations as
national surveillance systems, as they rely on reporters to
identify cases within eachmaternity unit and are susceptible
to under-ascertainment. In the case of the Netherlands, we
had no reported cases entered into the data entry system; as
a result, they were only included in the estimate of
incidence. For the Finnish registry data, case notification
relied on ICD-10 codes for the identification of cases with
anaphylaxis. Consequently, the sample was still vulnerable
to false negatives, and was reliant on the accuracy of the
coding of clinical data for the identification of women with
anaphylaxis. The validation of cases resulted in the removal
of over half of the women identified using ICD-10 codes. In
addition, as the sample was retrospective, it is possible that
the management of anaphylaxis was historically different to
that during the period of the prospective data collection for
the rest of the study.
In conclusion, across five European countries,
anaphylaxis related to pregnancy is similarly rare, despite
having a multitude of causative agents and different
prophylaxis protocols. It is imperative that current
international management protocols are followed, which
include immediate administration of adrenaline. Against
the background of increased medicalisation of childbirth,
an accurate drug allergy history and a visible signal of an
allergy, for example, a coloured wristband, may prevent a
medical error from causing a potentially fatal reaction.
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